Pragmatic clinical trials: ethical imperatives and opportunities

Shona Kalkman; Ghislaine J.M.W. van Thiel; Diederick E. Grobbee; Johannes J.M. van Delden

doi:10.1016/j.drudis.2018.06.007

Pragmatic clinical trials: ethical imperatives and opportunities

Shona Kalkman^*
, Ghislaine J.M.W. van Thiel
, Diederick E. Grobbee
, Johannes J.M. van Delden

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	1919-1921
Number of pages	3
Journal	Drug Discovery Today
Volume	23
Issue number	12
DOIs	https://doi.org/10.1016/j.drudis.2018.06.007
Publication status	Published - 1 Dec 2018

Access to Document

10.1016/j.drudis.2018.06.007

PragmaticFinal published version, 259 KBLicence: Taverne

Cite this

@article{5a867db534ac4940bd0b7afbb8829dc2,

title = "Pragmatic clinical trials: ethical imperatives and opportunities",

author = "Shona Kalkman and \{van Thiel\}, \{Ghislaine J.M.W.\} and Grobbee, \{Diederick E.\} and \{van Delden\}, \{Johannes J.M.\}",

note = "Funding Information: The research leading to these results was conducted as part of the IMI GetReal consortium. For further information please refer to www.imi-getreal.eu. This paper only reflects the personal views of the stated authors. The authors thank Kit Roes for his input on the thinking that went into this paper. The work leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115546, resources of which are composed of financial contribution from the EU's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies{\textquoteright} in-kind contribution. Funding Information: The research leading to these results was conducted as part of the IMI GetReal consortium. For further information please refer to www.imi-getreal.eu . This paper only reflects the personal views of the stated authors. The authors thank Kit Roes for his input on the thinking that went into this paper. The work leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115546 , resources of which are composed of financial contribution from the EU{\textquoteright}s Seventh Framework Programme ( FP7/2007-2013 ) and EFPIA companies {\textquoteright} in-kind contribution. Funding Information: The research leading to these results was conducted as part of the IMI GetReal consortium. For further information please refer to www.imi-getreal.eu. This paper only reflects the personal views of the stated authors. The authors thank Kit Roes for his input on the thinking that went into this paper. The work leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115546, resources of which are composed of financial contribution from the EU's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies? in-kind contribution.",

year = "2018",

month = dec,

day = "1",

doi = "10.1016/j.drudis.2018.06.007",

language = "English",

volume = "23",

pages = "1919--1921",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Pragmatic clinical trials

T2 - ethical imperatives and opportunities

AU - Kalkman, Shona

AU - van Thiel, Ghislaine J.M.W.

AU - Grobbee, Diederick E.

AU - van Delden, Johannes J.M.

N1 - Funding Information: The research leading to these results was conducted as part of the IMI GetReal consortium. For further information please refer to www.imi-getreal.eu. This paper only reflects the personal views of the stated authors. The authors thank Kit Roes for his input on the thinking that went into this paper. The work leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115546, resources of which are composed of financial contribution from the EU's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution. Funding Information: The research leading to these results was conducted as part of the IMI GetReal consortium. For further information please refer to www.imi-getreal.eu . This paper only reflects the personal views of the stated authors. The authors thank Kit Roes for his input on the thinking that went into this paper. The work leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115546 , resources of which are composed of financial contribution from the EU’s Seventh Framework Programme ( FP7/2007-2013 ) and EFPIA companies ’ in-kind contribution. Funding Information: The research leading to these results was conducted as part of the IMI GetReal consortium. For further information please refer to www.imi-getreal.eu. This paper only reflects the personal views of the stated authors. The authors thank Kit Roes for his input on the thinking that went into this paper. The work leading to these results has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115546, resources of which are composed of financial contribution from the EU's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies? in-kind contribution.

PY - 2018/12/1

Y1 - 2018/12/1

UR - https://www.scopus.com/pages/publications/85048927164

U2 - 10.1016/j.drudis.2018.06.007

DO - 10.1016/j.drudis.2018.06.007

M3 - Editorial

C2 - 29906514

AN - SCOPUS:85048927164

SN - 1359-6446

VL - 23

SP - 1919

EP - 1921

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 12

ER -

Pragmatic clinical trials: ethical imperatives and opportunities

Access to Document

Other files and links

Cite this